Navigation Links
China Diagnostic Reagent Industry Report, 2012-2014

DUBLIN, Ireland, March 26, 2013 /PRNewswire/ --

Research and Markets announces the addition of "China Diagnostic Reagent Industry Report, 2012-2014" to its catalogue.


China's diagnostic reagent industry has formed a certain market scale and basis, and is marching from the introduction stage to the growth stage. With the continuous growth in China's medical care investment and per capita health care spending, the China's diagnostic reagent market has a promising prospect.

In vitro diagnostic reagents account for more than 90.0% of the output of China's diagnostic reagent industry. In 2011, the market scale of in vitro diagnostic reagents reached about RMB 11.4 billion in China, the industry will maintain a growth rate of 15%-20% in the future, and the market scale will hit RMB 20.8 billion in 2015.

At present, there are only a few integrated in vitro diagnostic reagent enterprises with strong strength in China's diagnostic reagent market, including KHB and Fosun Pharma; other enterprises such as Da An Gene, BioSino, Leadman and Livzon have competitive advantages in specific fields such as biochemical diagnosis, immunodiagnosis, and molecular diagnosis.

Meanwhile, China's in vitro diagnostic reagent industry concentration is low. Among 300-400 enterprises, there are only about 20 enterprises with annual sales of more than RMB 100 million. The enterprises are generally small and have a few product varieties. In 2011, KHB, Da An Gene, BioSino, Leadman only occupied 3.8%, 2.3%, 1.9%, 1.6% of the market respectively.

Key Topics Covered:

1. Overview of Diagnostic Reagent Industry

2. China Diagnostic Reagent Industry
2.1 Overview
2.2 Market Structure
2.3 Import and Export
2.3.1 Import
2.3.2 Export
2.4 Competitive Landscape
2.4.1 Biochemical Diagnostic Reagents
2.4.2 Immune Diagnostic Reagents
2.4.3 Molecular Diagnostic Reagents
2.4.4 Integrated In Vitro Diagnostic Reagents
2.5 Profitability
2.6 Entry Barriers
2.6.1 Technical Barriers
2.6.2 Quality and Brand Barriers
2.6.3 Marketing Channel Barriers
2.6.4 Market Access Barriers

3. Development Environment of China Diagnostic Reagent Industry
3.1 Policy Environment
3.1.1 Regulatory Policy
3.1.2 Industry Policy
3.2 Upstream and Downstream Industries
3.2.1 Industrial Chain
3.2.2 Upstream
3.2.3 Downstream

4. Development Forecast of China Diagnostic Reagent Industry
4.1 Overall Forecast
4.1.1 Market Demand Drivers
4.1.2 Market Scale Forecast
4.2 Development Trends of Diagnostic Reagent Industry
4.2.1 Biochemical Diagnosis and Immunodiagnosis Will Still Be the Mainstream
4.2.2 Industry Concentration Will Increase
4.2.3 Enterprises with Complete Product Line Integrating Reagents and Instruments will Win

5. Major Chinese Diagnostic Reagent Enterprises

Selected Charts

Companies Mentioned

- Acon Biotech (Hangzhou)
- Beijing Kinghawk Pharmaceutical
- Beijing Leadman Biochemistry
- Beijing North Institute of Biological Technology (BNIBT)
- Beijing Wantai Biological Pharmacy Enterprise
- BioSino Bio-technology and Science
- Blue Cross Bio-Medical (Beijing)
- Da An Gene
- Inverness Medical (Shanghai)
- Livzon Pharmaceutical Group
- Shanghai Fosun Pharmaceutical (Group)
- Shanghai Kehua Bio-engineering
- Shanghai Rongsheng Biotech
- Shanghai Upper Bio-Tech Pharma
- Shenzhen PG Biotech

For more information please visit Research and Markets.

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contact Details

Research and Markets
Laura Wood , Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Sector: Diagnostics

SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
2. China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise
3. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
4. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
5. 3SBio Inc. to Present at the UBS Greater China Conference 2012
6. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform:
7. Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
8. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
9. Sigma-Aldrich Opens New Wuxi Packaging and Quality Control Facilities to Enhance Capabilities Serving China and Asia-Pacific Region
10. China Cord Blood Corporation Announces Completion of $65 Million Convertible Debt Financing with KKR
11. China Biologic Has Announced the Resignation of CFO Y. Tristan Kuo and Named Mr. Ming Yang as Interim CFO
Post Your Comments:
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... event of the year and one of the premier annual events for pharmaceutical ... ran from 8–11 November 2015, where ISPE hosted the largest number of attendees ...
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... 2015 SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
Breaking Biology Technology:
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... the explosion of technology-enabled health and wellness, and the ... book, The Internet of Healthy Things ... or smartphones even existed, Dr. Kvedar, vice president, Connected ... health care delivery, moving care from the hospital or ...
Breaking Biology News(10 mins):